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Background: Endocardial pacing may be beneficial in patients who fail to improve following
conventional epicardial cardiac resynchronization therapy (CRT). The potential to pace anywhere
inside the left ventricle thus avoidingmyocardial scar and targeting the latest activating segments
may be particularly important. The WiSE-CRT system (EBR systems, Sunnyvale, CA) reliably
produces wireless, endocardial left ventricular (LV) pacing. The purpose of this analysis was to
determinewhether this system improved symptoms or led to LV remodeling in patients whowere
nonresponders to conventional CRT.
Method: An international, multicenter registry of patients who were nonresponders to conven-
tional CRT and underwent implantation with theWiSE-CRT systemwas collected.
Results: Twenty-two patients were included; 20 patients underwent successful implantationwith
confirmation of endocardial biventricular pacing and in 2 patients, therewas a failure of electrode
capture. Eighteen patients proceeded to 6-month follow-up; endocardial pacing resulted in a
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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significant reduction in QRS duration compared with intrinsic QRS duration (26.6 ± 24.4 ms;
P = .002) and improvement in left ventricular ejection fraction (LVEF) (4.7 ± 7.9%; P = .021). The
mean reduction in left ventricular end-diastolic volume was 8.3 ± 42.3 cm3 (P = .458) and left
ventricular end-systolic volume (LVESV) was 13.1 ± 44.3 cm3 (P = .271), which were statistically
nonsignificant. Overall, 55.6% of patients had improvement in their clinical composite score and
66.7% had a reduction in LVESV≥15% and/or absolute improvement in LVEF≥5%.
Conclusion:Nonresponders to conventional CRThave few remaining treatment options.Wehave
shown in this high-risk patient group that the WiSE-CRT system results in improvement in their
clinical composite scores and leads to LV remodeling.
K EYWORD S
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1 INTRODUCTION
The management of cardiac resynchronization therapy (CRT) nonre-
sponders who remain symptomatic following intervention remains
difficult.1,2 It is estimated that CRT nonresponders account for
approximately 30%of all implants.1 Many of these patients have organ
dysfunction and comorbidities that preclude advanced heart failure
therapies, such as left ventricular (LV) assist devices or heart transplan-
tation. Indeed, only a small proportion of patients with severe LV sys-
tolic dysfunction receive advanced therapies.3 Occasionally, reversible
causes for nonresponse can be found and addressed such as subopti-
mal atrioventricular interval timings, inadequate biventricular pacing
fromventricular ectopyor atrial arrhythmias, insufficientmedical ther-
apyor anemia.4 Patientswith LV leadsmayhave restrictions that result
in suboptimal anatomical positioning or placement in close proximity
to myocardial scar and patients with persisting mechanical dyssyn-
chrony cannot be further optimized following conventional CRT.4-6
Endocardial LV pacing has a number of advantages over epicardial
pacing and may offer a treatment alternative in these nonresponder
patients. Endocardial pacing results in a more physiological acti-
vation, access to fast endocardial activation, and a pacing location
unconstrained by the coronary anatomy, thus enabling areas of latest
activation to be targeted while avoiding myocardial scar. LV endocar-
dial pacing, delivered using lead-based technology, has shown promise
in the treatment of nonresponders.7 Biffi et al demonstrated in an
analysis of the ALSYNC study that in 28 prior nonresponders, LV
endocardial pacing resulted in reverse remodeling in 47% of patients.8
However, lead-based LV endocardial pacing is limited by thromboem-
bolic complications.9 Additionally, there is no specifically designed
equipment or leads to deliver endocardial pacing and it remains
technically challenging with limited options available for placement
of the lead. The WiSE-CRT system (EBR systems, Sunnyvale, CA)
provides wireless, endocardial LV pacing and has been shown to
reliably produce biventricular pacing.10 The purpose of this analysis
was to determine the efficacy of theWiSE-CRT system in patients who
were nonresponders to conventional epicardial CRT.
2 METHODS
2.1 Study cohort
Patients who were nonresponders to conventional CRT and under-
went implantation with the WiSE-CRT system were further investi-
gated by performing a subanalysis of theWiSE-CRT study, SELECT-LV
study, and WiCS-LV Post Market Surveillance Registry (Clinical trial
study number NCT02610673).10,11 Patients with heart failure who
met the standard criteria for CRT based on the European Society
of Cardiology/European Heart Rhythm Association guidelines and
were CRT nonresponders were included. Patients were identified as
CRT nonresponders if they had no change or worsening of symptoms
or New York Heart Failure (NYHA) functional class after at least 6
months of CRT. In addition, any reversible causes, such as anemia or
low biventricular pacing, were addressed prior to inclusion. There was
no mandate for CRT optimization prior to inclusion because this is not
routinely recommended in guidelines. The exclusion criteria have been
described previously.10,11 Patients who did not meet the eligibility
criteria, for example, left ventricular ejection fraction (LVEF) > 35%,
but who the physician felt would benefit from endocardial pacingwere
discussed on a case-by-case basis to decide whether they should be
included.
2.2 Implant procedure
Eligible patients underwent ultrasonic acoustic window screening to
identify potential intercostal spaces for placement of the transmitter.
Spaces with a shallow angle to the basal posterior left ventricle and
with no lung encroachment during breathing exercises were selected
as suitable locations. The procedure started with placement of the
transmitter within the preidentified intercostal space by dissecting
down to the intercostal muscle and confirming using ultrasound,
that there is indeed an adequate window to the left ventricle. The
transmitter is then sutured into place with the battery placed in
the mid-axillary line. During the second stage of the procedure, the
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endocardial electrode is inserted either via a retrograde aortic or
trans-septal approach. Different myocardial segments are tested to
identify the optimal location for placement of the electrode and this
is then deployed within the chosen LV segment. Based on the center’s
practice, patients on long-term anticoagulation for atrial fibrillation
were allowed to hold anticoagulation for 2-3 days before implant and
then restart afterward. During the electrode implant, intravenous
heparin was administered to ensure an activated clotting time over
200s.
2.3 Study endpoints
Any procedural and postprocedure complications from implant to
6 months were recorded. Patients were assessed at 6 months post
WiSE-CRT implantation to determine their clinical progress. Patients
were considered to have improved with endocardial pacing if they
showed improvement in their clinical composite score consisting of no
hospitalizations with decompensated heart failure, survival to follow-
up, improvement of ≥1 NYHA functional class, or improvement in
their global assessment.1 Additionally, we considered patients to have
shown reverse LV remodeling if they had an absolute improvement in
LVEF of ≥5% and/or reduction of left ventricular end-systolic volume
(LVESV) of≥15%.
2.4 Statistical analysis
The results are presented as mean ± standard deviation for normally
distributed variables and as median (interquartile range) for nonnor-
mally distributed variables. When investigating the change from base-
line variables, a paired sample t-test was used for normally distributed
data andWilcoxon signed-rank test for not-normally distributed data.
A X2 was used for among-group comparisons or a Fisher’s exact test
if the expected cell count was less than five. A two sided P-value
of < .05 was considered statistically significant. Statistical analyses
were performed using Prism (GraphPad Software Inc., Version 8, San
Diego, CA) and SPSS (IBM Switzerland, Version 25, Switzerland).
3 RESULTS
Twenty-two patients were implanted with theWiSE-CRT system after
being identified as nonresponders to conventional CRT. The baseline
patient demographics are provided in Table 1. Patients were 67.6± 7.3
years, 90.0%male, 45.5% had an ischemic cardiomyopathy, and 54.5%
suffered from atrial fibrillation. The mean NYHA functional class was
2.9± 0.4, mean epicardial biventricular pacedQRS durationwas 167.2
± 29.2 ms, and LVEF was 26.4 ± 8.0%. Ischemic versus nonischemic
patients were more likely to have undergone previous cardiac surgery
(60 vs 0%; P = .003), have hypertension (80 vs16.7%; P = .008), and
have suffered a previous cerebrovascular accident (40 vs 0%;P= .035).
However, there was no significant difference in LVEF (P = .207), left
ventricular end-diastolic volume (P= .335), nor LVESV (P= .539).
F IGURE 1 Individual changes in QRS duration following
WiSE-CRT implantation.
Note: Blue line denotes the reduction in QRS duration following
WiSE-CRT implantation and red line denotes the broadening of QRS
duration followingWiSE-CRT implantation
[Color figure can be viewed at wileyonlinelibrary.com]
3.1 WiSE-CRT system procedure
Implantation was successful in all patients with biventricular endo-
cardial pacing confirmed following the procedure in 20 patients. In
two patients, we were unable to achieve biventricular pacing due to
the failure of electrode capture from poor transducer coverage with
no other intercostal spaces available for implantation. Early compli-
cations within 1 week included: one patient developed a right femoral
artery fistula requiring surgical repair, one patient developed a femoral
pseudoaneurysm requiring embolization, and one patient required
antibiotics for cellulitis at the generator site. Late complications
from 1 week to 6 months included: one patient developed a pocket
hematoma treated conservatively, one patient required antibiotics for
cellulitis at the generator site, two patients required a system revision
due to a defective transmitter, and one patient developed a generator
pocket infection at 3 months requiring removal of the subcutaneous
system. There were no thromboembolic complications.
3.2 Clinical response and LV remodeling
After 6 months follow-up, 1 patient had the device removed as
described above, 1 patient was lost to follow-up, and 18 patients pro-
ceeded for clinical and echocardiographic review. Biventricular pacing
was assessed at 6 months and tracking > 95% was observed in 86.7%
of patients. There was a significant reduction in the QRS duration fol-
lowing WiSE-CRT implantation compared with intrinsic QRS duration
(26.6 ± 24.4 ms; P = .002) (Figure 1) and baseline epicardial biventric-
ular pacing (26.2 ± 32.0 ms; P = .004) (Table 2). Additionally following
WiSE-CRT implantation, there was a significant improvement in LVEF
(25.4± 7.9 vs 30.2± 10.7%; P= .021) but a nonsignificant reduction in
LV end-diastolic volume (235.0 ± 90.7 vs 226.7 ± 106.2 cm3; P = .458)
and LVESV (184.1 ± 82.7 vs 171.0 ± 87.3 cm3; P = .271) (Figures 2
and 3). Overall, 40% (6/15) of patients had a reduction in LVESV of
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TABLE 1 Baseline patient demographics






Age (years) 67.6± 7.3 69.0± 7.6 66.2± 7.2 .365
Male (%) 20 (90.9) 10 (1.0) 10 (0.8) .481
Comorbidities (%)
Cardiac surgery 6 (27.3) 6 (60.0) 0 (0.0) .003
Atrial fibrillation 12 (54.5) 5 (50.0) 7 (58.3) 1.000
Hypertension 10 (45.5) 8 (80.0) 2 (16.7) .008
Diabetes mellitus
a
6 (28.6) 2 (20.0) 4 (36.4) .635
Cerebrovascular accident
a
4 (19.0) 4 (40.0) 0 (0.0) .035
NewYork Heart Association functional class 2.9± 0.4 3.1± 0.3 2.7± 0.5 .055
Left bundle branch block
b
(%) 14 (82.4) 5 (62.50) 9 (100.0) .082
Biventricular epicardial pacedQRS duration (ms) 167.2± 29.2 153.9± 18.1 177.8± 32.7 .083
Echocardiography
Left ventricular ejection fraction (%) 26.4± 8.0 24.0± 6.6 28.4± 8.8 .207
Left ventricular end-diastolic volume (cm3) 230.4± 91.7 253.9± 83.3 206.4± 98.5 .335
Left ventricular end-systolic volume (cm3) 177.3± 83.2 191.0± 68.4 165.1± 96.9 .539
aData available for 21 patients.
bData available for 17 patients.
TABLE 2 Volumetric remodeling followingWiSE-CRT implantation
Variables BeforeWiSE-CRT implantation AfterWiSE-CRT implantation P-value
NewYork Heart Association functional class 2.9± 0.5 2.7± 0.8 .317
Biventricular QRS duration (ms)
a
167.6± 30.0 141.3± 30.7 .004
Left ventricular ejection fraction (%) 25.4± 7.9 30.2± 10.7 .021
Left ventricular end-diastolic volume (cm3) 235.0± 90.7 226.7± 106.2 .458
Left ventricular end-systolic volume (cm3) 184.1± 82.7 171.0± 87.3 .271
aData available for 17 patients.
F IGURE 2 Individual changes in LVEF followingWiSE-CRT
implantation.
Note: Blue line denotes the improvement in LVEF followingWiSE-CRT
implantation and red line denotes the worsening of LVEF following
WiSE-CRT implantation
[Color figure can be viewed at wileyonlinelibrary.com]
≥15%, 50% (9/18) of patients had an absolute reduction in LVEF of
≥5%, and 66.7% of patients had a reduction in LVESV ≥15% and/or
absolute improvement in LVEF≥5%. Therewasno significant change in
NYHA functional status afterWiSE-CRT implantation (2.9 ± 0.5 vs 2.7
±0.8;P= .317); however, 10 (55.6%) patients had improvement in their
clinical composite scores. There was no significant difference between
ischemic andnonischemic cardiomyopathy in termsof change inNYHA
functional class, QRS duration, and LV function following WiSE-CRT
implantation. Similarly, no differencewas found between patientswith
a history of atrial fibrillation, hypertension, or cerebrovascular events.
3.3 Identifying a nonresponder cohort likely to
improvewith theWiSE-CRT system
We performed a subanalysis to determine which nonresponders to
conventional CRT were unlikely to improve with a WiSE-CRT system.
Weonly considered patients to have improvedwith theWiSE-CRT sys-
tem if they had an absolute improvement in LVEF≥5%and/or improve-
ment in LVESV of ≥15%. Patients who failed to improve compared
with those who remodeled had similar baseline demographics; age
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F IGURE 3 Box andwhisker plots showing changes in left ventricular function followingWiSE-CRT implantation [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 4 Bull’s-eye plot showing the final location of the
WiSE-CRT electrode relative to the epicardial lead.
Note: Themyocardial segment with the epicardial lead is represented
by a circle, theWiSE-CRT electrode is represented by a triangle, and a
star demonstrates the position for both the lead and electrodewas
similar. Patients whowere cardiac resynchronization therapy
nonresponders are shown as red and responders as blue
[Color figure can be viewed at wileyonlinelibrary.com]
(70.4 ± 3.8 vs 66.2 ± 8.4 years; P = .323), ischemic cardiomyopathy
(66.7 vs 33.3%; P = .321), male (100 vs 91.2%; P = 1.000), atrial
fibrillation (66.7 vs 50.0%; P = .638), and hypertension (66.7 vs 33.3%;
P = .321). Patients who failed to respond with the WiSE-CRT system
had a nonsignificant trend toward a narrower epicardial biventricular
paced QRS duration (156.3 ± 26.8 vs 172.6 ± 29.9 ms; P = .278),
worse NYHA functional class (3.1 ± 0.4 vs 2.8 ± 0.5; P = .076),
severely impaired LVEF (24.2 ± 4.6 vs 26.1 ± 9.2%; P = .640), more
dilated LV end-diastolic volume (267.0 ± 83.3 vs 213.7 ± 93.7 cm3;
P = .280), and more dilated LVESV (210.8 ± 65.1 vs 172.3 ± 94.5 cm3;
P = .519). In addition, we investigated the location of the WiSE-CRT
endocardial electrode relative to the original LV lead to determine
how this influenced volumetric remodeling. We compared the pro-
cedural fluoroscopy and postoperative antero-posterior and lateral
chest X-rays together. The lateral chest X-ray was not available in
eight patients so were excluded from the analysis; seven patients
had volumetric remodeling and three did not. In patients who did not
display volumetric remodeling, the endocardial electrode was placed
in a similar location to the epicardial lead and was placed in a mid to
apical location. In patients who improved, six (85.7%) patients had the
electrode placed in a different myocardial segment to the epicardial
lead and all were implanted in the lateral wall in a predominantly mid
LV position (Figure 4).
4 DISCUSSION
CRT nonresponse is defined heterogeneously in terms of volumetric
remodeling, clinical improvement, or both.1 The management of these
patients remains challenging and few alternative/proven treatment
options currently exist. In this current analysis, we have demonstrated
that 55.6% of nonresponders to conventional CRT improved their
clinical composite scores and 66.7% had a reduction in LVESV ≥15%
and/or absolute improvement in LVEF ≥5% with endocardial CRT.
We feel this degree of clinical and volumetric improvement with
the WiSE-CRT system in a difficult patient group is promising and
may offer a viable treatment option for them, although this must be
weighed against the invasive nature of the intervention and potential
for harm.
4.1 Comparisonwith prior studies
Nonresponders to CRT are regarded as a heterogeneous and challeng-
ing group to treat, who often suffer from multiple comorbidities.8,9
Accordingly, we found a substantial number of patients who had
several comorbidities, including atrial fibrillation, hypertension, and
prior cerebrovascular accidents. Following implantation, there was
SIDHU ET AL. 971
no significant improvement in NYHA functional class but 55.6% of
patients showed improvement in their clinical composite scores.
Furthermore, there was a significant reduction in QRS duration with
endocardial pacing compared with epicardial biventricular pacing of
26.2 ± 32.0 ms (P = .004) and improvement in LVEF of 4.7 ± 7.9%
(P = .021). There was no significant reduction in LV end-diastolic or
end-systolic volume, which is likely a reflection of the small patient
cohort and follow-up period of only 6 months. Overall, few studies
have compared the effects of endocardial pacing in just CRT nonre-
sponders. One notable exceptionwas theALSYNC study, whereby 118
patients were implanted with an endocardial lead; 90 (76.2%) with a
failed epicardial lead or suboptimal coronary sinus anatomy and 28
(23.8%)were nonresponders to previousCRT, using a similar definition
of “nonresponse” as our study.8,12 In the nonresponder cohort at 6
months, 47% of patients had an improvement in LVESV of ≥15%, and
5% had an improvement ≥30%. Our results of wireless, leadless LV
endocardial pacing are similar; 40% of patients had an improvement in
LVESVof≥15%, and 13.3%had an improvement≥30%. In theALSYNC
study, 19% of endocardial leads could not be fixated at the desired
location. Given that CRT nonresponders are an already difficult group
who are perhaps less likely to respond, the ability to choose from any
pacing location is extremely vital in improving outcomes and is an
important benefit with theWiSE-CRT system.13
Endocardial pacing places patients at additional risks related to the
procedure and thromboembolic events, with the later an ongoing risk
with trans-septal leads requiring lifelong anticoagulation.9 The WiSE-
CRT system uses leadless pacing, which may reduce this long-term
thromboembolic risk. However, the overall risk of endocardial pacing
in solely nonresponders to conventional CRT, who are regarded as a
more complex patient group, has not been fully explored and needs
further assessment in larger studies.
4.2 Identifying the nonresponder group likely to
improvewith endocardial pacing
Nonresponders to epicardial CRT are a sicker patient group with
multiple comorbidities. This places them at a higher risk of procedural
complications, especially from general anesthesia, which is often
required for WiSE-CRT implantations. Therefore, it will be important
to identify which nonresponders are more likely to improve and thus
should be considered for endocardial pacing rather than those whose
heart failure has progressed such that endocardial pacing is unlikely
to be beneficial. Although our study was not powered to detect a
statistically significant difference in baseline demographics in patients
who underwent endocardial pacing who failed to show volumetric
remodeling, we found that these patients tended to be older, with
ischemic cardiomyopathy and atrial fibrillation. These characteristics
are known to give an unfavorable response to conventional CRT.1
Interestingly, patients who failed to respond with WiSE-CRT pacing
had a nonsignificant trend toward a narrower baseline epicardial
biventricular paced QRS duration (156.3 ± 26.8 vs 172.6 ± 29.9 ms;
P = .278), suggesting that patients who were already relatively well
resynchronized with conventional CRT are less likely to have incre-
mental benefit with endocardial pacing. Additionally, patients who
did not respond to WiSE-CRT had a trend toward a more severely
impaired and dilated left ventricle at baseline, again suggesting that
in these patients, their heart failure has progressed to a point where
any further interventions, including endocardial pacing, are unlikely
to have a positive effect. The position of the electrode relative to the
LV lead may also be important since patients who did not improve
following endocardial pacing were more likely to have the electrode
implanted within the same myocardial segment. Furthermore, guiding
endocardial pacing to the optimal desired location has been shown
to improve outcomes and will be particularly important in these CRT
nonresponders.13,14 Although this subanalysis is limited by a small
cohort, it does suggest that implanting patients with less comorbidi-
ties, broad epicardial biventricular pacedQRS duration, a left ventricle
that is not so severely dilated and implanting the electrode in a differ-
ent location to the LV lead is perhapsmore likely to result in a favorable
response following WiSE-CRT implantation. The ongoing SOLVE-CRT
clinical trial is a randomized-controlled, international, multicenter trial
of the WiSE-CRT system and will provide further information on key
demographics that may result in a favorable response to endocardial
pacing and in those who respond, whether the improvement is due
to endocardial pacing itself or due to pacing in a different myocardial
segment, which is more optimal to pace.15
5 LIMITATIONS
This study has the same limitations inherent with any prospectively
collected data. However, we tried to reduce this bias by standardizing
data collection. The small patient numbers limit the generalizability of
the paper; however, as already discussed, the outcomes of nonrespon-
ders to conventional CRT who undergo endocardial pacing are sparse.
Indeed, the ALSYNC study was the largest published study in the
literature and included only 28 nonresponders.12 It would have been
important to determine how long patients had been nonresponders to
conventional CRT; however, this was outside the scope of this paper.
Biventricular pacing was only estimated at 6 months and cannot be
fully relied upon without attaching a 24 h-Holter monitor to look for
ectopy or arrhythmia. This monitoring was not undertaken in these
studies. We did not record the number of patients who were too
sick to undergo acoustic window screening and implantation of the
WiSE-CRT system. This estimate would have helped to understand
how many CRT nonresponders were felt ineligible to undergo this
invasive procedure. This may have also resulted in underrepresenta-
tion of ischemic patients who are generally regarded as more unwell
than nonischemic patients as evidenced by only 45.5% of ischemic
patients in this study, similar to the ALSYNC study that included
42.9%.8 Ischemic patients have a greater potential to benefit from
targeted endocardial pacing.14,16 An accurate Simpson’s biplane was
not possible for all patients and a change in LVEF ≥5% was, therefore,
used but it is appreciated that this is a less reliable estimate of outcome
than reduction in LV systolic volume≥15%.
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6 CONCLUSION
Patients who fail to respond to conventional CRT are a complex
patient group with multiple comorbidities. The WiSE-CRT system
reliably produces endocardial biventricular pacing and has a number
of advantages in these patients, including the option to pace in any
location, thus avoiding myocardial scar and targeting latest activating
segments. We have shown that this system results in both a clinical
and volumetric improvement, which is particularly important in these
patients who have few alternative treatment options. Further studies
are required to determine the overall benefit in such patients, and the
results of the ongoing SOLVE-CRT trial will be important.
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